Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
77 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2014', provides an overview of the Basal Cell Carcinoma (Basal Cell Epithelioma)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Basal Cell Carcinoma (Basal Cell Epithelioma) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Basal Cell Carcinoma (Basal Cell Epithelioma) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Basal Cell Carcinoma (Basal Cell Epithelioma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Basal Cell Carcinoma (Basal Cell Epithelioma) Overview 8 Therapeutics Development 9 Pipeline Products for Basal Cell Carcinoma (Basal Cell Epithelioma) - Overview 9 Pipeline Products for Basal Cell Carcinoma (Basal Cell Epithelioma) - Comparative Analysis 10 Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics under Development by Companies 11 Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics under Investigation by Universities/Institutes 13 Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Basal Cell Carcinoma (Basal Cell Epithelioma) - Products under Development by Companies 17 Basal Cell Carcinoma (Basal Cell Epithelioma) - Products under Investigation by Universities/Institutes 18 Basal Cell Carcinoma (Basal Cell Epithelioma) - Companies Involved in Therapeutics Development 19 4SC AG 19 Biofrontera AG 20 Biosceptre International Limited 21 Bristol-Myers Squibb Company 22 Genextra S.p.a. 23 InMed Pharmaceuticals Inc. 24 Mayne Pharma Group Limited 25 MediGene AG 26 Novartis AG 27 Oncovir, Inc. 28 Transgene SA 29 Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics Assessment 30 Assessment by Monotherapy Products 30 Assessment by Combination Products 31 Assessment by Target 32 Assessment by Mechanism of Action 34 Assessment by Route of Administration 36 Assessment by Molecule Type 38 Drug Profiles 40 aminolevulinic acid hydrochloride - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 ASN-002 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 BIL-010t - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 BMS-833923 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 CIGB-128 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 CS-S/BCC-1 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 CS-TATI-1 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 DAC-0060 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 erismodegib - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 itraconazole - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 LEQ-506 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Oshadi D + Oshadi R - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Poly-ICLC - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 sinecatechins - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Small Molecules to Inhibit Casein Kinase 1 for Cancer - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 Basal Cell Carcinoma (Basal Cell Epithelioma) - Recent Pipeline Updates 62 Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects 71 Basal Cell Carcinoma (Basal Cell Epithelioma) - Discontinued Products 72 Basal Cell Carcinoma (Basal Cell Epithelioma) - Product Development Milestones 73 Featured News & Press Releases 73 Sep 17, 2014: Novartis presents oncology research advances with new data on sonidegib at ESMO 2014 73 Jul 22, 2014: Biosceptre Announces Positive Phase I Results for BIL-010t to Treat Basal Cell Carcinoma 73 Jun 01, 2014: Pivotal data for Novartis' investigational compound LDE225 show marked tumor responses in advanced basal cell carcinoma 74 Feb 19, 2014: Novartis investigational compound LDE225 met primary endpoint in pivotal trial for patients with advanced basal cell carcinoma 75 Appendix 76 Methodology 76 Coverage 76 Secondary Research 76 Primary Research 76 Expert Panel Validation 76 Contact Us 77 Disclaimer 77
List of Tables Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H2 2014 9 Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma) - Comparative Analysis, H2 2014 10 Number of Products under Development by Companies, H2 2014 12 Number of Products under Investigation by Universities/Institutes, H2 2014 13 Comparative Analysis by Late Stage Development, H2 2014 14 Comparative Analysis by Clinical Stage Development, H2 2014 15 Comparative Analysis by Early Stage Development, H2 2014 16 Products under Development by Companies, H2 2014 17 Products under Investigation by Universities/Institutes, H2 2014 18 Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by 4SC AG, H2 2014 19 Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Biofrontera AG, H2 2014 20 Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Biosceptre International Limited, H2 2014 21 Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Bristol-Myers Squibb Company, H2 2014 22 Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Genextra S.p.a., H2 2014 23 Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by InMed Pharmaceuticals Inc., H2 2014 24 Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Mayne Pharma Group Limited, H2 2014 25 Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by MediGene AG, H2 2014 26 Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Novartis AG, H2 2014 27 Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Oncovir, Inc., H2 2014 28 Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Transgene SA, H2 2014 29 Assessment by Monotherapy Products, H2 2014 30 Assessment by Combination Products, H2 2014 31 Number of Products by Stage and Target, H2 2014 33 Number of Products by Stage and Mechanism of Action, H2 2014 35 Number of Products by Stage and Route of Administration, H2 2014 37 Number of Products by Stage and Molecule Type, H2 2014 39 Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics - Recent Pipeline Updates, H2 2014 62 Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects, H2 2014 71 Basal Cell Carcinoma (Basal Cell Epithelioma) - Discontinued Products, H2 2014 72
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.